A Novel Immunomodulatory and Molecularly Targeted Strategy for Refractory Hodgkin’s Lymphoma

Oncotarget - United States
doi 10.18632/oncotarget.1468
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Treatment of Relapse and Refractory Hodgkin Lymphoma

Oncogematologiya
OncologyHematology
2017English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie
Oncology
2016English

CD30-targeted Oncolytic Viruses as Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Oncotarget
Oncology
2018English

Management of Patients With Non-Hodgkin’s Lymphoma: Focus on Adoptive T-Cell Therapy

ImmunoTargets and Therapy
AllergyImmunology
2015English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Hodgkin´s Lymphoma and Autoimmunity: Is There a Relationship?

Acta Medica Portuguesa
Medicine
2015English

Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation

Case Reports in Medicine
Medicine
2016English

Tandem Autologous-Haploidentical Transplantation Is a Feasible and Effective Program for Refractory Hodgkin Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2017English

Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report

Drugs in R and D
Pharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy